Nebivolol and Panobinostat: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Nebivolol
Panobinostat
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased CYP2D6 substrate exposure
Interaction Deep Dive
Coadministration of dextromethorphan (a CYP2D6 substrate) with panobinostat (a CYP2D6 inhibitor) caused highly variable increases in dextromethorphan exposure in 1 pharmacokinetic study. Avoid coadministration of panobinostat with sensitive CYP2D6 substrates or CYP2D6 substrates with a narrow therapeutic index, as increased exposure of the CYP2D6 substrate may occur. Frequent monitoring is warranted if coadministration is unavoidable1.
Why it happens (mechanism)
Inhibition of CYP2D6-mediated metabolism by panobinostat
Literature reports
1 report — tap to read
a) Coadministration of dextromethorphan with panobinostat caused highly variable increases in dextromethorphan exposure in 1 pharmacokinetic study. Cmax and AUC of dextromethorphan (a CYP2D6 substrate) increased by 80% (interquartile ranges: 20% to 200%) and 60% (interquartile ranges: 20% to 130%), respectively, from baseline levels in patients with advanced cancer when a single dose was added to an existing panobinostat 20 mg regimen (n=14) 1.
Common questions
Can I take Nebivolol and Panobinostat together?
Increased CYP2D6 substrate exposure Always confirm with your pharmacist or prescriber before making any change.
How serious is the Nebivolol and Panobinostat interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Nebivolol or Panobinostat need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: FARYDAK(R) oral capsules, panobinostat oral capsules. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2015. DailyMed
Keep reading about Nebivolol
Keep reading about Panobinostat
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist